GlassScriptPhysician profile
Afeefa K Chaudhry
NPI 1770552564
$2,286.76
in general payments reported to CMS, 2019-2025
30 companies · $862 in 2025
The $862 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2021: $18.02 · 2022: $34.10 · 2023: $542 · 2024: $521 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $275.33 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $215.29 | 2023-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $188.27 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Sumitomo Pharma America, INC. | $186.51 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $166.08 | 2022-2025 | Shingrix, Arexvy |
| Eisai INC. | $108.45 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $107.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.07 | 2023-2024 | Trintellix |
| Amgen INC. | $98.48 | 2019-2025 | Repatha, Otezla, Repatha |
| Corcept Therapeutics | $89.72 | 2024-2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $86.56 | 2019 | |
| Exact Sciences Corporation | $71.01 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $65.39 | 2023-2025 | Vraylar |
| Mylan Specialty L.P. | $56.24 | 2019-2023 | Yupelri |
| Astellas Pharma US INC | $52.88 | 2019-2023 | Veozah |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $43.71 | 2023-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.65 | 2024-2025 | Xifaxan, Trulance |
| Lundbeck LLC | $40.34 | 2025 | Vyepti |
| Dynavax Technologies Corporation | $39.17 | 2024-2025 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $33.70 | 2025 | Rexulti |
| Corium, LLC | $33.33 | 2023 | Adlarity |
| Avvisto Therapeutics, LLC | $29.59 | 2024-2025 | Cycloset |
| Inspire Medical Systems, INC. | $26.91 | 2025 | Inspire |
| Kyowa Kirin, INC. | $24.25 | 2025 | |
| Ibsa Pharma INC. | $23.35 | 2024 | Licart, Flector, Tirosint |
| Allergan, INC. | $18.05 | 2019 | |
| Pfizer INC. | $18.02 | 2021 | |
| Merck Sharp & Dohme LLC | $18.02 | 2024 | Capvaxive |
| Abbott Laboratories | $15.39 | 2025 | Proclaim |
| Idorsia Pharmaceuticals US INC | $13.67 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afeefa Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.